Sanctuary Advisors LLC Buys Shares of 68,875 Stryker Corporation $SYK

Sanctuary Advisors LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 68,875 shares of the medical technology company’s stock, valued at approximately $21,685,000.

Other institutional investors also recently modified their holdings of the company. Gables Capital Management Inc. bought a new position in Stryker in the second quarter valued at about $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the second quarter valued at approximately $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the 4th quarter valued at approximately $26,000. Sankala Group LLC bought a new stake in Stryker during the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC acquired a new position in Stryker in the 2nd quarter valued at approximately $27,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 0.1%

Shares of Stryker stock opened at $329.86 on Monday. The stock’s 50-day moving average is $326.99 and its 200 day moving average is $332.39. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Piper Sandler lowered their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. BTIG Research decreased their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.